TY - JOUR
T1 - A) Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial.
AU - Nista, Enrico Celestino
AU - Candelli, Marcello
AU - Cremonini, Filippo
AU - Cazzato, Immacolata Alessia
AU - Zocco, Maria Assunta
AU - Franceschi, Francesco
AU - Cammarota, Giovanni
AU - Gasbarrini, Giovanni Battista
AU - Gasbarrini, Antonio
PY - 2004
Y1 - 2004
N2 - The incidences of nausea, diarrhoea and epigastric pain in patients treated with B. clausii were significantly lower than in placebo group, in both PP and ITT analysis. Equally, intensity of nausea and diarrhoea in patients treated with B. clausii was significantly lower than in placebo group. There were no differences in adherence to treatment and H. pylori eradication rates between groups. Conclusion : In symptom-free, H. pylori-positive subjects B. clausii bacteriotherapy reduces the incidence of the most common side-effects related to anti-H. pylori antibiotic therapy compared with placebo
AB - The incidences of nausea, diarrhoea and epigastric pain in patients treated with B. clausii were significantly lower than in placebo group, in both PP and ITT analysis. Equally, intensity of nausea and diarrhoea in patients treated with B. clausii was significantly lower than in placebo group. There were no differences in adherence to treatment and H. pylori eradication rates between groups. Conclusion : In symptom-free, H. pylori-positive subjects B. clausii bacteriotherapy reduces the incidence of the most common side-effects related to anti-H. pylori antibiotic therapy compared with placebo
KW - Bacillus clausii
KW - HP
KW - Bacillus clausii
KW - HP
UR - http://hdl.handle.net/10807/21036
M3 - Article
SN - 0269-2813
SP - 1181
EP - 1188
JO - ALIMENTARY PHARMACOLOGY & THERAPEUTICS
JF - ALIMENTARY PHARMACOLOGY & THERAPEUTICS
ER -
